Bergamid-Racing Wheel-Application snapshot_0429 CONSUMER ELECTRONICS BRAND G E A R O F R A C I N G W H E E L • Achieve high strength and abrasion resistance • Deliver smooth, quiet functionality and minimize backlash for improved control • Delivered glass fiber reinforced nylon formulation to meet the requirements for high strength and abrasion resistance • Offered local service and support, which helped to accelerate production • Provided stable supply despite the nylon shortage issues in the market Bergamid™ Polymer Formulation KEY REQUIREMENTS WHY AVIENT?

FITNESS SMARTWATCH BRAND S M A R T W A T C H H O U S I N G • Reduce carbon footprint at least 30% by using bio-based material • Meet physical properties requirements such as impact strength, UV resistance, and thermal resistance • Provide small lot quantity for various colors • Offered bio-based colorants to support carbon footprint reduction • Maintained over 80% of mechanical properties of materials and passed QSUN & QUV test • Offered supply flexibilities in low volume for a high mix of colors OnColor Bio Colorants KEY REQUIREMENTS WHY AVIENT?

ORTHOPEDIC PARTS MANUFACTURER O R T H O P E D I C S O L E I N S E R T • A super soft TPE (

ATTRIBUTE PC PUMP CMG 6000 Metering throughput High – Volumetric/gravimetric V V/G Data export/network – Yes Touch screen – Yes Multiple log-in levels – Yes Multiple log-in levels – No www.avient.com Copyright © 2020, Avient Corporation.

Trilliant™ HC high performance formulations were developed for specific healthcare enclosure needs, including: • Chemical resistance to common disinfectants • UL 94 ratings of 5VA at 3.0, V-0 at 1.5 mm & V-1 at 0.75 mm • Retained color aesthetics after chemical exposure • Ability to utilize existing PC/PET & COPE tooling Tested using an adaptation from ASTM D543 for environmental stress cracking resistance (ESCR), 15 bars of each material were placed into jigs at 1% and 2% strain.

RG-404/U) are defined in U.S. military specification MIL-C-17E. Formulations for material performance over 300°F (150°C).

Avient Launches Halogen-Free Flame-Retardant TPE Grades Made with Sustainable Raw Materials for USB-C Cable Jackets Avient Launches Halogen-Free Flame-Retardant TPE Grades made with sustainable raw materials for USB-C Cable Jackets.

ACTIVE INGREDIENT RELEVANT INGREDIENTS CaviCide™ 46781-6 Quaternary Ammonium Isopropanol 2-Butoxyethanol Super Sani-Cloth® 9480-4 Quaternary Ammonium Isopropanol SporGon™ N/A Hydrogen Peroxide Peracetic Acid N/A Vesphene® IIse 1043-87 2-Phenylphenol 4-Tert-Amylphenol Potassium Hydroxide Sodium Hydroxide Virex® TB 70627-2 Quaternary Ammonium Diethylene Glycol Butyl Ether Clorox® Disinfecting Wipes 5813-79 Quaternary Ammonium Hexoxyethanol Isopropanol Ethoxylated Alcohols Lysol® All-Purpose Cleaner 67619-10 Quaternary Ammonium 1-Phenoxy-2-Propanol Ethanolamine Dipropylene Glycol Formula 409® Heavy Duty Degreaser N/A N/A Propylene Glycol Butyl Ether Ethanolamine Table 1. R.; Richards, C. C.; Gaynes, R.

Polymer Diagnostics Inc. 33587 Walker Road Avon Lake, Ohio 44012 United States +1 800 438 2335 +1 440 930 1644 fax Polymer Diagnostics Inc. is a contract laboratory with accreditation to ISO/IEC 17025 by the American Association for Laboratory Accreditation (A2LA) for both chemical and mechanical capacities. 17.2 8 .25 in 8 .5 in 17 C M Y K HC_Industry bulletin_PDI_fi nal.indd REMAY 78810 TR: 16.5000" x 11.6875" and 17.000" x 11.000" Digital/IAM BL: 17.2500" x 11.9375" FINAL: 8.2500" x 11.6875" and 8.500" x 11.000" 11.6875 in 25 in 11.9375 in 8 .25 in 8 .5 in 11 in i n Asset No. 78810 Polymer Diagnostics Inc. is a wholly-owned subsidiary of PolyOne Corporation. PDI has extensive experience with the testing of medical devices and materials including: • Catheters • Bio-implants • Surgical diagnostic devices • Medical tubing • Other disposable medical devices Issues often arise as a result of: • Improper design or choice of material • The environment of exposure • Processing conditions World-class people and capabilities under one roof • Failure Analysis/Prevention • Qualifi cation Support • Rheology • Polymer Characterization • Deformulation • Physical Testing • Litigation Support • Characterization of polymers in pharmaceutical delivery systems • Phthalate and BPA testing 17.2 8 .25 in 8 .5 in 17 C M Y K HC_Industry bulletin_PDI_fi nal.indd REMAY 78810 TR: 16.5000" x 11.6875" and 17.000" x 11.000" Digital/IAM BL: 17.2500" x 11.9375" FINAL: 8.2500" x 11.6875" and 8.500" x 11.000" 11.6875 in 25 in 11.9375 in 8 .25 in 8 .5 in 11 in i n Asset No. 78810 Polymer Diagnostics Inc. is a wholly-owned subsidiary of PolyOne Corporation. Polymer Diagnostics Inc. 33587 Walker Road Avon Lake, Ohio 44012 United States +1 800 438 2335 +1 440 930 1644 fax Polymer Diagnostics Inc. is a contract laboratory with accreditation to ISO/IEC 17025 by the American Association for Laboratory Accreditation (A2LA) for both chemical and mechanical capacities. 17.2 8 .25 in 8 .5 in 17 C M Y K HC_Industry bulletin_PDI_fi nal.indd REMAY 78810 TR: 16.5000" x 11.6875" and 17.000" x 11.000" Digital/IAM BL: 17.2500" x 11.9375" FINAL: 8.2500" x 11.6875" and 8.500" x 11.000" 11.6875 in 25 in 11.9375 in 8 .25 in 8 .5 in 11 in i n Asset No. 78810

Microsoft PowerPoint - AVNT Q3 2024 Earnings Presentation_10.29_12PM AVIENT CORPORATION T H I R D Q U A R T E R 2 0 2 4 R E S U L T S A N D 2 0 2 4 F I N A N C I A L G U I D A N C E (NYSE: AVNT) O C T O B E R 3 1 , 2 0 2 4 DISCLAIMER Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. FX +8.5% FX -0.4% Total Avient +8.1% Note: Regional Sales Percentages exclude impact of foreign exchange COLOR, ADDITIVES & INKS SEGMENT (Q3 2024 PERFORMANCE VS Q3 2023) $487 $522 Q3 23 Q3 24 $89 $97 Q3 23 Q3 24 Sales Adjusted EBITDA (in millions) (in millions) Sales Adjusted EBITDA 7 + 7% (+8% excluding FX) + 9% (+11% excluding FX) 18.3% +40 bps *18.7% * * Adjusted EBITDA Margin % • Sales growth driven by winning new product specifications in consumer & packaging, strong underlying demand in healthcare and improving demand in building & construction • Favorable mix and raw material deflation contributed to EBITDA margin expansion SPECIALTY ENGINEERED MATERIALS SEGMENT (Q3 2024 PERFORMANCE VS Q3 2023) $268 $295 Q3 23 Q3 24 $51 $57 Q3 23 Q3 24 Sales Adjusted EBITDA (in millions) (in millions) Sales Adjusted EBITDA 8 • Sales growth driven by restocking in healthcare & consumer end markets and strong underlying demand for composite applications used in building & construction, energy and defense end markets • Favorable mix contributed to EBITDA margin expansion + 10% (+10% excluding FX) + 12% (+13% excluding FX) 19.0% +40 bps *19.4% * * Adjusted EBITDA Margin % 2024 G U IDA N CE FY 2024 GUIDANCE Previous (Aug 6) Current Adjusted EPS $2.55 to $2.70 $2.63 to $2.67 Adjusted EBITDA $515 to $540 million $525 to $530 million Interest Expense $105 million $104 million Adjusted Effective Tax Rate 23% to 25% 23% to 25% Capital Expenditures & Investment in S/4 Hana ~$140 million ~$140 million 10 11 • Investor Day to be held December 4, 2024 at the NYSE, beginning at 10AM • The focus will be to do a deep dive on the Company’s strategy • Registration and microsite will be available in early November 2024 AVIENT INVESTOR DAY AP P EN D IX 18 Performance Additives 15% Pigments 13% TiO2 9% Dyestuffs 2% Polyethylene 10%Nylon 5% Polypropylene 4% Styrenic Block Copolymer 4% Other Raw Materials 38% ~40% hydrocarbon based (Grey shaded materials are hydrocarbon based, includes portion of “Other Raw Materials”) Non-hydrocarbon based materials RAW MATERIAL BASKET SEGMENT DATA U.S. & Canada 41% EMEA 36% Asia 18% Latin America 5% 2023 SEGMENT, END MARKET AND GEOGRAPHY GEOGRAPHY REVENUESEGMENT FINANCIALS Consumer 19% Packaging 23%Industrial 16% Building and Construction 9% Telecommunications 4% Energy 5% Defense 7% END MARKET REVENUE $2,007M $358M $1,138M $224M Sales EBITDA Specialty Engineered Materials Color Additives and Inks $502M$3,143M (1) Transportation 10% Healthcare 7% 20 (1) Total company sales and adjusted EBITDA of $3,143M and $502M, respectively, include intercompany sales eliminations and corporate costs 2023 REVENUE | $2 .0 B ILL ION US & Canada 34% EMEA 37% Asia 21% Latin America 8% END MARKET REGION 21 Packaging 34% Consumer 21% Healthcare 8% Industrial 15% Transportation 9% Building & Construction 10% Telecommunications 1% Energy 2% COLOR, ADDITIVES & INKS 2023 REVENUE | $1 .1 B ILL ION US & Canada 52% EMEA 35% Asia 13% 22 Packaging 5% Consumer 16% Healthcare 6%Industrial 16% Transportation 12% Telecommunications 9% Energy 10% Defense 18% Building & Construction 8% END MARKET REGION SPECIALTY ENGINEERED MATERIALS Packaging 32% Consumer 26% Healthcare 9% Industrial 13% Building & Construction 6% Telecommunications 2% Energy 2% Defense 1% Asia (18% of sales) Transportation 9% 2023 AVIENT REGIONAL SALES Packaging 25% Consumer 13% Healthcare 5% Industrial 18% Building & Construction 9% Energy 5% Defense 8% EMEA (36% of sales)Transportation 13% Packaging 13% Consumer 22% Healthcare 10% Industrial 16% Building & Construction 12% Energy 6% Defense 8% US & Canada (41% of sales) Transportation 9% Packaging 59% Consumer 22% Healthcare 2% Industrial 8% Building & Construction 4% LATAM (5% of sales) Transportation 5% Telecommunications 4% Telecommunications 4% 23 BY END MARKET Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.